BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, May 5, 2024
Home
»
Newsletters
» BioWorld MedTech
BioWorld MedTech
Sep. 7, 2016
View Archived Issues
Danaher to buy Cepheid for $4B with an eye on diagnostics growth runway
Washington-based Danaher Corp. (NYSE: DHR) determined that buying molecular diagnostics company Cepheid Inc. (NASDAQ: CPHD) will boost its position in the molecular diagnostics space, but Danaher's investors may take more convincing.
Read More
CFDA proposes priority review pathway for new medical devices
Read More
SSRI effects are too much of a good thing for bones
Read More
Telehealth app Mydoc aims to ease medical cost strains in Singapore
Read More
Appointments and advancements
Read More
Financings
Read More
Daily M&A
Read More
Other news to note
Read More
MDD's Oncology Extra
Read More